September 30, 2014 7:37 PM ET

Biotechnology

Company Overview of Gilead Colorado, Inc.

Company Overview

Gilead Colorado, Inc. offers discovery, development, and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders in the United States and Europe. The company has two oral endothelin receptor antagonist product candidates in late-stage clinical development: ambrisentan, which is in Phase 3 clinical development for the treatment of patients with pulmonary arterial hypertension; and darusentan, which completed a Phase 2b clinical trial for the treatment of patients with resistant hypertension. It also licenses manufacturing, development, and commercialization rights for ambrisentan to GlaxoSmithKline in various territories outside of the United States thro...

7575 West 103rd Avenue

Suite 102

Westminster, CO 80021

United States

Founded in 1996

160 Employees

Phone:

303-410-6666

Fax:

303-410-6667

Key Executives for Gilead Colorado, Inc.

Founder
Age: 69
Chief Financial Officer
Age: 62
Senior Vice President of Clinical Development & Regulatory Affairs
Age: 61
Senior Vice President of Commercial Operations & Medical Affairs
Age: 67
Vice President of Corporate Development
Age: 44
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Microbes BioSciences, Inc. United States
SpherIngenics, Inc. United States
HDSono, Inc. United States
Aramed, Inc. United States
BioQuanta Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Gilead Colorado, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.